PF4 and COVID-19: Pre‐clinical and clinical studies revealed the participation of CXCL4 and its receptor, CXCR3, in multiple cardiovascular diseases of different etiologies including atherosclerosis, hypertension, cardiac hypertrophy, and heart failure.[53] In addition, the recently reported association of COVID‐19 vascular pathogenesis with elevated expression of a number of cytokines, including CCL4 and CXCL family chemokines,[54] suggests that CF may also protect against vascular inflammatory damage induced by the virus.